Does initial surveillance in early prostate cancer reduce the chance of cure by radical prostatectomy? A case-control study

Scandinavian Journal of Urology and Nephrology

Volumn 37, Issue 3, 2003, Pages 213-217

  Khatami, Ali ^a   Damber, Jan Erik ^a   Lodding, Pär ^a   Pihl, Carl Gustaf ^a   Hugosson, Jonas ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Prostate cancer; Radical prostatectomy; Screening; Surveillance

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SCREENING; CANCER STAGING; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; EARLY CANCER; EARLY DIAGNOSIS; GLEASON SCORE; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SCORING SYSTEM; TUMOR GROWTH; TUMOR VOLUME;

AGED; BIOPSY, NEEDLE; FOLLOW-UP STUDIES; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; MONITORING, PHYSIOLOGIC; NEOPLASM STAGING; OBSERVATION; PROBABILITY; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REFERENCE VALUES; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; SWEDEN; TIME FACTORS; TREATMENT OUTCOME;

EID: 0038387787     PISSN: 00365599     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365590310008073     Document Type: Article

References (27)

1. Walsh PC, Partin AW. Treatment of early stage prostate cancer: radical prostatectomy. Important Adv Oncol 1994: 211-23.
2. Wallner K, Roy J, Harrison L. Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. J Clin Oncol 1996; 14: 449-53.
3. Stone NN, Stock RG. Prostate brachytherapy: treatment strategies. J Urol 1999; 162: 421-6.
4. Shipley WU, Thames HD, Sandler HM, Hanks GE, Zietman AL, Perez CA, et al. Radiation therapy for clinically localized prostate cancer. A multi-institutional pooled analysis. JAMA 1999; 281: 1598-604.
5. Bolla M, Gonzales D, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and Goserelin. N Engl J Med 1997; 337: 295-300.
6. Adolfsson J. Deferred treatment of low grade stage T3 prostate cancer without distant metastases. J Urol 1993; 149: 326-8, discussion 328-9.
7. Whitmore WF Jr. Expectant management of localized prostate cancer. Cancer 1991; 67: 1091-6.
8. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. Long-term survival among men with conservatively treated localized prostate cancer. JAMA 1995; 274: 626-31.
9. Andriole GL, Catalona WJ. The diagnosis and treatment of prostate cancer. Annu Rev Med 1991; 42: 9-15.
10. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993; 71 (3 Suppl): 933-8.
11. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271: 368-74.
12. Lundberg S, Berge T. Prostatic carcinoma. An autopsy study. Scand J Urol Nephrol 1970; 4: 93-7.
13. Franks LM. The incidence of carcinoma of prostate: an epidemiological survey. Recent Results Cancer Res 1972; 39: 149-55.
14. Boccon-Gibod L. Significant versus insignificant prostate cancer - can we identify the tigers from the pussy cats? J Urol 1996; 156: 1069-70.
15. Epstein JI, Carmichael M, Partin AW, Walsh PC. Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup. J Urol 1993; 149: 1478-81.
16. Epstein JI, Walsh PC, Carter HB. Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c disease. J Urol 2001; 166: 1688-91.
17. Carter HB, Walsh PC, Landis P, Epstein JI. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol 2002; 167: 1231-4.
18. Epstein JI, Partin AW, Sauvageot J, Walsh PC. Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol 1996; 20: 286-92.
19. McNeal JE, Villers AA, Redwine EA, Freiha FS, Stamey TA. Capsular penetration in prostate cancer. Significance for natural history and treatment. Am J Surg Pathol 1990; 14: 240-7.
20. Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM. Biological determinants of cancer progression in men with prostate cancer. JAMA 1999; 281: 1395-400.
21. Adolfsson J, Ronstrom L, Lowhagen T, Carstensen J, Hedlund PO. Deferred treatment of clinically localized low grade prostate cancer: the experience from a prospective series at the Karolinska Hospital. J Urol 1994; 152: 1757-60.
22. Johansson JE. The natural course of untreated, localized primary prostate carcinoma Urologe A 1996; 35: 446-8.
23. Hugosson J, Aus G, Bergdahl C, Bergdahl S. Prostate cancer mortality in patients surviving more than 10 years after diagnosis. J Urol 1995; 154: 2115-7.
24. Hugosson J, Aus G. Natural course of localized prostate cancer. A personal view with a review of published papers. Anticancer Res 1997; 17 (Suppl 3A): 1441-8.
25. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998; 280: 975-80.
26. Stamey TA, Johnstone IM, McNeal JE, Lu AY, Yemoto CM. Preoperative serum prostate specific antigen levels between 2 and 22 ng/ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng/ml. J Urol 2002; 167: 103-11.
27. Zietman AL, Thakral H, Wilson L, Schellhammer P. Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy. J Urol 2001; 166: 1702-6.